Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jack Kavanaugh
AddedMar 31, 2024
UpdatedMay 31, 2026
Jack Kavanaugh

Jack Kavanaugh

Founder & CEO, Nanotech Energy

CrunchbaseLinkedIn

Jack Kavanaugh's Career

Nanotech Energy
Nanotech Energy

Los Angeles, CA, US

Founder & CEO· C-Suite · Management
ZetaRx Biosciences
ZetaRx Biosciences

Seattle, WA, US

Founder
Arrogene
Arrogene

Santa Monica, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jack Kavanaugh's Career

Nanotech Energy
Nanotech Energy
Series D$94.9M752014Los Angeles, CA, US
Founder & CEO· C-Suite · Management
ZetaRx Biosciences
ZetaRx Biosciences
Seed$2.8M52009Seattle, WA, US
Founder

Similar to ZetaRx Biosciences

ZZ BiotechZZ BiotechHouston, TX, USBiologic Treatmentsest. 2006ZZ BiotechHouston, TX, US · est. 2006

ZZ Biotech LLC: A Houston-based clinical stage biotech firm innovating treatments for neurological diseases.

Series A · $7.9M9
Rjs BiologicsRjs BiologicsSeattle, WA, USMedicines, Pharmaceuticalsest. 2009Rjs BiologicsSeattle, WA, US · est. 2009

RJS Biologics: Innovating critical treatments as a leading pharmaceutical manufacturer.

Angel · $225k5
Zetagen TherapeuticsZetagen TherapeuticsSyracuse, NY, USBone Growth Productsest. 2015Zetagen TherapeuticsSyracuse, NY, US · est. 2015

ZetaGen Therapeutics develops innovative bone growth products using a unique molecular pathway.

Series B · $14.4M5
ProsettaProsettaSan Francisco, CA, USDrug Developmentest. 2013ProsettaSan Francisco, CA, US · est. 2013

Prosetta Biosciences: A US-based biotech firm specializing in drug discovery and development.

Series D · $33M29
Arrogene
Arrogene
Seed$7.9M102007Santa Monica, CA, US
Board Member· Board

Leadership at Arrogene

Eggehard HollerEggehard HollerCo-Founder
Larry A. CoutureLarry A. CoutureCEO
Alexander LjubimovAlexander LjubimovCo-Founder
Julia Y. LjubimovaJulia Y. LjubimovaCo-Founder

Similar to Arrogene

SynerGene TherapeuticsSynerGene TherapeuticsPotomac, MD, USCancer Therapeuticsest. 1998SynerGene TherapeuticsPotomac, MD, US · est. 1998

SynerGene Therapeutics: A biopharmaceutical firm innovating nanotech cancer treatments.

Series A · $10.3M5
NanoPharmaceuticalsNanoPharmaceuticalsRensselaer, NY, USTherapeuticsest. 2013NanoPharmaceuticalsRensselaer, NY, US · est. 2013

Clinical-stage company innovating targeted therapeutics for cancer and inflammatory diseases.

Pre-Seed · $6M7
Ariz Precision MedicineAriz Precision MedicineDavis, CA, USDrug Developmentest. 2015Ariz Precision MedicineDavis, CA, US · est. 2015

ARIZ: Developing early-stage cancer drug candidates for effective disease eradication.

Pre-Seed · $2.7M2
Angarus TherapeuticsAngarus TherapeuticsPortola Valley, CA, USTherapeuticsest. 2018Angarus TherapeuticsPortola Valley, CA, US · est. 2018

Angarus: Innovating precise immuno-oncology therapies for a targeted and powerful cancer attack.

Series A · $11.3M75

Jack Kavanaugh's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Jack Kavanaugh

Mike FrancisMike FrancisCo-Founder · NanotechBryce KnightBryce KnightCo-Founder · Revenue.comGeorge DiloyanGeorge DiloyanCEO · Nanotech Industrial SolutionsTim WilliamsTim WilliamsCo-Founder · NanoThingsOnyema OsuagwuOnyema OsuagwuCEO · BioNanoTechJohn JarvisJohn JarvisCo-Founder · Nanotech